2025/7/22
Polaris Group (TWSE:6550) announces its US California subsidiary Polaris Pharmaceuticals Inc. (PPI) an exclusive licensing agreement with Bioprofarma Bagó (a fully owned subsidiary of GRUPO EMPRESARIAL BAGO) in Buenos Aires, Argentina to introduce ADI-PEG20 (ADZODI), a novel treatment for Malignant Pleural Mesothelioma (MPM) to the LATAM. This partnership is set to improve the treatment landscape by delivering innovative therapeutic solution aimed at improving patient outcomes across the region.
Under the terms of this agreement, Polaris will develop and manufacture the product, and Bioprofarma Bagó will hold the marketing authorization rights and be responsible for registering, importing, and promoting it in the LATAM region. The agreement enables Bioprofarma Bagó to enter this pathology, which has very few therapeutic alternatives, while also strengthening its position among demanding companies seeking partners capable of managing and maintaining agreements of this nature.
Steve Hsu, CEO of Polaris Pharmaceuticals, stated:
“We are very excited about this partnership with Bioprofarma Bagó s as one of leading pharmaceutical companies in the LATAM region. This partnership not only strengthens our alliance but also highlights our shared dedication to expanding access to critical oncology and rare disease treatments. This collaboration with Bioprofarma Bagó reflects Polaris’s ideal strategic partnership model to bring new treatment options to people living with serious cancer diseases.”.
Leonardo Fernández, General Manager of Bioprofarma Bagó, stated:
“We are excited about this collaboration with Polaris, a pioneer in advanced therapies. It is truly gratifying to have developed this project together and to ensure a promising future for both companies. I want to emphasize our responsible role as healthcare companies seeking to contribute to a worthy cause: helping patients find hope in ADZODI® for their treatment and recovery. We are thrilled to have shared our mutual trust on this first occasion, confident that we will continue to strengthen the links between innovation and access to high-value treatments”.
About Polaris
Polaris Group is a biopharmaceutical company dedicated to pioneering advanced therapies, primarily focusing on metabolic-related diseases. Our lead drug candidate, ADI-PEG 20 (ADZODI), is still awaiting the response for the receiving the BLA from FDA for MPM. ADI‑PEG 20 is a biologic in late-stage clinical development for a wide range of cancers, including hepatocellular carcinoma, soft tissue sarcoma, glioblastoma, non-small cell lung cancer, melanoma, acute myeloid leukemia and others. ADI-PEG20 is designed to disrupt cancer cell metabolism, providing a novel approach to treating a wide range of cancers heavily influenced by metabolic pathways. Our mission is to revolutionize the treatment of complex diseases like cancer by concentrating on their metabolic foundations, ultimately striving to enhance patient outcomes globally.
About Bioprofarma Bagó SA
Established in Argentina, Bioprofarma Bagó SA is a member of the GRUPO EMPRESARIAL BAGÓ, headquartered in Buenos Aires, Argentina with subsidiaries throughout Latin America. Its presence in the Region for over 20 years makes it attractive to foreign companies seeking to out-license its innovation and expand their business to the Region. With well-known experience in therapeutic areas such as oncology, hematology, urology, and rare diseases, Bioprofarma Bagó has extensive expertise in high-cost and highly complex treatments. It is a patient-focused company that works closely with healthcare professionals and patient support programs. For more information, please visit: https://bioprofarma-bago.com.ar